
FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update
The investigational nonopioid analgesic cebranopadol was associated with a statistically significant and high level of pain reduction compared to placebo in adults undergoing bunionectomy, satisfying the primary endpoint of the pivotal ALLEVIATE-2 phase 3 …